Long COVID clinical trials/studies involving CBMPs (also including CBD/hemp-based supplements)
| NCT number | Title | Country | Status | Study design | Participants | Condition | Intervention | Publications |
|---|---|---|---|---|---|---|---|---|
| NCT04997395 | Feasibility of cannabidiol for the treatment of Long COVID | UK | Active, not recruiting | Phase 2, open label | Adults over 18. N = 30 | Long COVID | MediCabilis 5% CBD Oil (UK trade name: MediCabilis™ Cannabis sativa 50). Daily dose up to 150 mg CBD, 6 mg THC for 5 months | Not published |
| NCT05467904 | Double-blind randomized placebo-controlled trial of a proprietary full hemp flower formulation for Long COVID | USA | Not yet recruiting | Placebo controlled. Phase not stated | Adults 18–65. N = 111 | Post-acute COVID-19 syndrome (Long COVID) | Full hemp flower formulation (Xltran Plus™ and Xltran™) for 28 days | Not published |
| NCT04828668 | Study to evaluate benefits & safety of Endourage Formula C™ oral drops in people with post-acute COVID-19 syndrome | USA | Completed | Placebo controlled. Phase not stated | Adults 18–75. N = 60 | Post-acute COVID-19 syndrome (Long COVID) | Formula C™ sublingual drops for 28 days (Extracted from hemp flower) | Published [114] |
USA: United States of America; N: refers to the number of study participants